Table 3 Multivariate analyses of biomarkers for PFS and OS in 48 bmCRPC-patients on Enzalutamide-therapy without PSA-response
Progression Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|
Variable | HR (95% CI) | P | Variable | HR (95% CI) | P |
ALP rising at 12 weeks Yes No | 1 (reference) 0.77 (0.22–2.69) | 0.68 | ALP rising at 12 weeks Yes No | 1 (reference) 1.14 (0.32–4.09) | 0.83 |
ALP rising at 12 weeks, without LDH normalization Yes No | 1 (reference) 0.70 (0.18–2.67) | 0.6 | ALP rising at 12 weeks, without LDH normalization Yes No | 1 (reference) 0.31 (0.08–1.13) | 0.08 |
Enzalutamide after chemotherapy Yes No | 1 (reference) 0.55 (0.28–1.09) | 0.09 | Enzalutamide after chemotherapy Yes No | 1 (reference) 0.36 (0.17–0.78) | 0.01 |
ECOG > 0 Yes No | 1 (reference) 0.78 (0.41–1.49) | 0.44 | ECOG > 0 Yes No | 1 (reference) 0.77 (0.39–1.52) | 0.45 |
Visceral metastases Yes No | 1 (reference) 0.92 (0.44–1.92) | 0.82 | Visceral metastases Yes No | 1 (reference) 0.95 (0.44–2.05) | 0.89 |
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; bmCRPC: bone metastatic castration-resistant prostate cancer; PSA: prostate specific antigen; ECOG: eastern cooperative oncology group performance status | |||||